Long-term survival in metastatic pancreatic cancer. A case report and review of the literature

Journal of the Pancreas

Volumn 7, Issue 5, 2006, Pages 486-491

  Spinelli, Gian Paolo ^a   Zullo, Angelo ^b   Romiti, Adriana ^a   Di Seri, Marisa ^a   Tomao, Federica ^a   Miele, Evelina ^a   Spalletta, Bruno ^a   Eramo, Annarita ^b   Hassan, Cesare ^b   Tomao, Silverio ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy, adjuvant; Drug therapy; Pancreatic neoplasms; Survivors

Indexed keywords

ANGIOPEPTIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN C; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXALIPLATIN; PENTETREOTIDE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; ECHOTOMOGRAPHY; HEALTH STATUS; HEMATEMESIS; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LIVER SCINTISCANNING; MALE; MEDICAL LITERATURE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PERITONEUM METASTASIS; QUALITY OF LIFE; SURGICAL DRAINAGE; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY; TUMOR VOLUME;

ADENOCARCINOMA; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TIME FACTORS;

EID: 33748879113     PISSN: 15908577     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Saif MW, Sviglini H, Carpenter M. Impact of ethnicity on outcome in pancreatic carcinoma. JOP. J Pancreas (Online) 2005; 6:246-54. [PMID 15883478]
2. Matsuno S, Egawa S, Arai K. Trends in treatment for pancreatic cancer. J Hepatobiliary Pancreat Surg 2001; 8:544-8. [PMID 11956906]
3. Matsumoto G, Nagai S, Muta M, Tsuruta K, Okamoto A, Toi M. Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer. Oncol Rep 2003; 10:1201-6. [PMID 12883681]
4. el-Kamar FG, Grossbard ML, Kozuch PS. Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. Oncologist 2003; 8:18-34. [PMID 12604729]
5. Pasetto LM, Jirillo A, Stefani M, Monfardini S. Old and new drugs in systemic therapy of pancreatic cancer. Crit Rev Oncol Hematol 2004; 49:135-51. [PMID 15012974]
6. O'Connell MJ. Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 1985; 3:1032-9. [PM1D 3894585]
7. Arbuck SG. Overview of chemotherapy for pancreatic cancer. Int J Pancreatol 1990; 7:209-22. [PMID 2081925]
8. Andre T, Lotz JP, Bouleuc C, Azzouzi K, Houry S, Hannoun L, et al. Phase II trial of 5-Fluorouracil, Leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol 1996; 7:173-8. [PMID 8777174]
9. Rouger P, Ducreux M, Douillard J, Seitz JF, Bugat R, Bosset JF, et al. Efficacy of 5-FU + cisplatin compared to bolus 5-FU in advanced pancreatic carcinoma: a randomized trial from the French Anticancer Digestive Group. Proc Am Soc Clin Oncol 1999; 18:274a (Abstract 1114).
10. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985; 253:2061-7. [PMID 2579257)
11. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. J Clin Oncol 1986; 4:1794-8. [PMID 2946815]
12. Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, et al. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 1991; 68:965-9. [PMID 1833042]
13. Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65:2207-12. [PMID 2189551]
14. Mallinson CN, Rake MO, Cocking JB, Fox CA, Cwynarski MT, Diffey BL, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980; 281:1589-91. [PMID 7004559]
15. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [PMID 9196156]
16. Alberts SR, Townley PM, Goldberg RM, Cha SS, Sargent DJ, Moore DF, et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 2003; 14:580-5. [PMID 12649105]
17. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-16. [PMID 15908661]
18. Kurihara K, Nagai H, Kasahara K, Kawai T, Saito K, Kanazawa K. Pleomorphic carcinoma of the pancreas with massive lymphocytic stromal infiltration and long-term survival after resection. Int J Pancreatol 2000; 27:241-8. [PMID 10952407]
19. Toyooka S, Tsukuda K, Mizuta M, Soh J, Shirakawa K, Shimizu K, Shimizu N. A case of pancreatic adenocarcinoma with novel K-ras mutation and long term survival. Am J Gastroenterol 2002; 97:1852-3. [PMID 12135058]
20. Shimada K, Kosuge T, Yamamoto J, Yamasaki S, Sakamoto M. Successful outcome after resection of pancreatic cancer with a solitary hepatic metastasis. Hepatogastroenterology 2004; 51:603-5. [PMID 15086214]
21. Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA. Periampullary adenocarcinoma: Analysis of 5-year survivors. Ann Surg 1998; 227:821-31. [PMID 9637545]
22. Ozaki H, Kinoshita T, Kosuge T, Shimada K, Yamamoto J, Tokuye K, et al. Long-term survival after multimodality treatment for resectable pancreatic cancer. Int J Pancreatol 2000; 27:217-24. [PMID 10952404]
23. Yoshizawa K, Nagai H, Kurihara K, Sata N, Kawai T, Saito K. Long-term survival after surgical resection for pancreatic cancer. Hepatogastroenterology 2001; 48:1153-6. [PMID 11490822]
24. Tsuchiya R, Harada N, Tsunoda T, Miyamoto T, Ura K. Long-term survivors after operation on carcinoma of the pancreas. Int J Pancreatol 1988; 3:491-6. [PMID 3221109]
25. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165:68-72. [PMID 8380315]
26. Nagakawa T, Sanada H, Inagaki M, Sugama J, Ueno K, Konishi I, et al. Long-term survivors after resection of carcinoma of the head of the pancreas: significance of histologically curative resection. J Hepatobiliary Pancreat Surg 2004; 11:402-8. [PMID 15619016]
27. Watanabe I, Sasaki S, Konishi M, Nakagohri T, Inoue K, Oda T, Kinoshita T. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas 2004; 28:160-5. [PMID 15028948]
28. Halma MA, Wheelhouse NM, Barber MD, Powell JJ, Fearon KC, Ross JA. Interferon-gamma polymorphisms correlate with duration of survival in pancreatic cancer. Hum Immunol 2004; 65:1405-8. [PMID 15556691]
29. Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, Piemonti L, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004; 64:8420-7. [PMID 15548713]
30. Crown J, Casper ES, Botet J, Murray P, Kelsen DP. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9:1682-6. [PMID 1875224]
31. Bruckner HW, Crown J, McKenna A, Hart R. Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors. Cancer Res 1988; 48:5570-2. [PMID 3046742]
32. DeCaprio JA, Mayer RJ, Gonin R Arbuck SG. Fluorouracil and high dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991; 9:2128-33. [PMID 1960554]
33. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81:882-5. [PMID 8044610]
34. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593-600. [PMID 8879373]
35. Louvet C, Beerblock K, de Gramont.A, Varette C, Demuynck B, Bennamoun M, et al. High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: a pilot study. Eur J Cancer 1993; 29A:1217. [PMID 8518038]
36. Alberts SR, Townley PM, Goldberg RM, Cha SS, Moore DF Jr, Krook JE, et al. Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. Anti Oncol 2002; 13:553-7. [PMID 12056705]
37. Louvet C, Andre T. Lledo G, Hammel P, Bleiberg H, Bouleuc C, et al. Gemcitabine-oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): a Gercor multicenter phase II study. Proc Am Soc Clin Oncol 2001; 20:Abstract 506.
38. Garnier C, Rebischung C, Chirpaz E, Balosso J, Fournet J, Pasquier D, et al. Phase II study of a combination with leucovorin (LV), 5 FU bolus and infusion (FU), gemcitabine (GEM) and oxaliplatin (LOHP) (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC). Proc Am Soc Clin Oncol 2001; 20:Abstract 620.
39. Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94:481-5. [PMID 16434988]